HBC.OL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 10:25):

Stats
Today's Volume	43 478.00
Average Volume	250 425
Market Cap	825.72M
EPS	NOK-0.0955 ( 2023-03-31 )
Next earnings date	( NOK0 ) 2024-05-10
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-7.74
ATR14	NOK0.0420 (2.03%)

Hofseth BioCare ASA Correlation

10 Most Positive Correlations

10 Most Negative Correlations
SSG.OL	-0.816

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hofseth BioCare ASA Financials

Annual	2023
Revenue:	NOK190.82M
Gross Profit:	NOK-54.56M (-28.59 %)
EPS:	NOK-0.270

FY	2023
Revenue:	NOK190.82M
Gross Profit:	NOK-54.56M (-28.59 %)
EPS:	NOK-0.270

FY	2022
Revenue:	NOK120.45M
Gross Profit:	NOK28.51M (23.67 %)
EPS:	NOK-0.370

Financial Reports:

No articles found.

Hofseth BioCare ASA

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.